Categories: NewsSports medicine

Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com 

Staff

Recent Posts

TEDCO’s Maryland Innovation Initiative Announces FY2025 Technology Assessment Awards

Over $1 million awarded to 7 university projects  COLUMBIA, Md., April 24, 2025 /PRNewswire/ -- TEDCO,…

3 hours ago

RS and Siemens are paving the way to Industry 5.0 with I/O

RS offers Siemens IP6X distributed I/O systems engineered to satisfy organizations' ever-increasing demand for actionable…

3 hours ago

INAUGURAL FUTURE WAY FORWARD CONFERENCE INVITES AMERICA TO COME TOGETHER — FOR REAL AND FOR GOOD

Physician turned founder creates new opportunity for collaboration, growth, and positive social changeNASHVILLE, Tenn., April…

3 hours ago

KONZA National Network Joins Missouri eLTSS Project Phase 2 to Advance Person-Centered Care for Individuals with IDD

TOPEKA, Kan., April 24, 2025 /PRNewswire/ -- KONZA National Network is proud to announce its partnership…

3 hours ago

ApolloMD Partners with Cleo Health to Transform Emergency Medicine Documentation Through AI Innovation

ATLANTA, April 24, 2025 /PRNewswire/ -- ApolloMD, one of the nation's leading physician services organizations, today…

3 hours ago

BISSELL Takes on Shedding Season with its Most Powerful Stick Vacuum Yet

PowerClean® FurFinder™ and PowerClean® FurGuard™ cordless stick vacuums find and powerfully capture pet hair and…

3 hours ago